Imagine facing metastatic lung cancer, where the disease has spread beyond the lungs. This is a tough battle, as traditional treatments often struggle to keep the cancer at bay. A new study is testing whether adding a specific type of radiation therapy, called liver stereotactic ablative radiotherapy, to standard drug treatments can provide better outcomes for patients. The goal is to see if this combination can help patients live longer without their cancer progressing. If successful, this approach could offer new hope for those with advanced lung cancer, potentially giving them more quality time with family and friends. However, it’s important to remember that this is still in the testing phase, and results can vary. More research will help clarify the benefits and risks, but for now, this study shines a light on promising new options for patients in need.
Phase 2 Study: L-SABR Plus Standard Therapy in Metastatic NSCLC PatientsCould Targeted Radiation Therapy Offer Hope for Lung Cancer Patients?
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider L-SABR in metastatic NSCLC; results pending for progression-free survival impact.
This ongoing Phase 2 trial, sponsored by Memorial Sloan Kettering Cancer Center, investigates the efficacy of adding liver stereotactic ablative radiotherapy (L-SABR) to standard drug therapy, which includes anti-PD-(L)1 based immunotherapy and platinum-based chemotherapy, in patients with metastatic non-small cell lung cancer (NSCLC). The study aims to enroll 68 participants, with a primary endpoint of median progression-free survival. The trial began on December 9, 2022, and is expected to reach primary completion by December 9, 2026. Secondary endpoints and safety data will be evaluated, but specific results and statistical analyses are not yet available. Clinicians should consider the potential of L-SABR as an adjunctive treatment in metastatic NSCLC pending further data.
What this means for you:
New radiation therapy could give lung cancer patients more time with loved ones — a glimmer of hope in tough times. More on Non-Small Cell Lung Cancer
Meta-analysis of neoadjuvant anti-PD-1/PD-L1 plus chemotherapy in resectable NSCLC reports resection and response rates
Combining checkpoint inhibitors with chemotherapy helps more lung cancer patients get surgery safely
This meta-analysis synthesized outcomes from 1,885 patients with potentially resectable non-small cell lung cancer who received neoadjuvant …
A review of 1,885 patients found that adding immune therapy to standard chemo before surgery helped many get clean operations. About one in …
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
A systematic review and meta-analysis of real-world studies evaluated first-line pembrolizumab monotherapy for advanced NSCLC with high PD-L…
New data from thousands of patients shows pembrolizumab provides reliable long-term survival for advanced lung cancer without major safety s…
Pembrolizumab improves overall survival versus chemotherapy in Chinese patients with advanced NSCLC and PD-L1 expression
Five-year follow-up shows pembrolizumab extends life for Chinese lung cancer patients with high PD-L1
This Phase 3 trial evaluated pembrolizumab monotherapy against chemotherapy in Chinese patients with previously untreated locally advanced o…
A five-year look at a Chinese lung cancer trial shows pembrolizumab improved survival compared to chemotherapy for patients with high PD-L1 …
Network meta-analysis of anti-PD-1/PD-L1 regimens in advanced non-squamous NSCLC without EGFR or ALK alterations
New drugs beat old ones for advanced lung cancer survival
This systematic review and network meta-analysis evaluated overall survival and progression-free survival across 15 Phase III randomized cli…
New drug combinations show better survival chances for advanced lung cancer patients whether their tumors express PD-L1 or not
View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Intervention(s): L-SABR (RADIATION), Anti-PD-(L)1 based immunotherapy (BIOLOGICAL), Platinum based chemotherapy (DRUG)
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Primary Outcome(s): Median progression-free survival
Enrollment: 68 (ESTIMATED)
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Start: 2022-12-09 | Primary Completion: 2026-12-09
Real-world meta-analysis supports pembrolizumab for advanced NSCLC with high PD-L1
Real-world data confirms pembrolizumab offers long-term survival for advanced lung cancer patients
Related in Pulmonology & Critical Care
FDA Approves Provocholine (methacholine chloride) for Bronchial Airway Hyperreactivity Diagnosis
FDA approves new test to help diagnose asthma in certain patients
The FDA approved Provocholine (methacholine chloride) for diagnosing bronchial airway hyperreactivity in adults and children aged 5 years an…
The FDA approved Provocholine, a drug used in a breathing test to diagnose airway hyperreactivity in people aged 5 and older who may have as…
Tislelizumab plus chemotherapy improves survival in extensive-stage small cell lung cancer
Immunotherapy combo extends survival in small cell lung cancer
This phase 3 RCT evaluated tislelizumab plus chemotherapy versus placebo plus chemotherapy in previously untreated extensive-stage small cel…
Adding tislelizumab to chemo helped people with extensive-stage small cell lung cancer live 2 months longer, a phase 3 trial shows.
Lower PEEP may increase ventilator-free days in ventilated patients without ARDS
Lower breathing pressure settings showed modest benefits for some critically ill patients without lung injury
This Bayesian re-analysis of an RCT in 980 invasively ventilated critically ill patients without ARDS found that lower PEEP (0-5 cm H2O) com…
A re-analysis of data found that using the lowest safe breathing pressure might help some patients breathe easier. However, the overall bene…
Machine learning models show moderate accuracy predicting neoadjuvant immunotherapy response in NSCLC
Machine learning models predict how well lung cancer patients respond to immunotherapy
This systematic review and meta-analysis of 44 models found that machine learning predicts neoadjuvant immunotherapy response in resectable …
A new analysis of 44 models shows computer programs can guess which lung cancer patients will benefit from immunotherapy, though the study h…
From Other Specialties
Post-extubation dysphagia incidence ranges from 28.36% to 68.94% in critically ill children
High rates of swallowing problems found in children after intubation
This scoping review of 15 studies examines the incidence and predictors of pediatric post-extubation dysphagia (PED). The authors identify h…
Many critically ill children struggle to swallow safely after breathing tubes are removed, with some studies showing issues in up to 69% of …
Circular RNAs may regulate ferroptosis and anti-tumor immunity in cancer via multiple mechanisms
Circular RNAs may offer new ways to target cancer cells
This systematic review explores how circular RNAs (circRNAs) act as molecular bridges to simultaneously regulate ferroptosis and anti-tumor …
New research identifies circular RNAs as molecular bridges that could help doctors diagnose and treat cancer more precisely.
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
A 6 dimension and 42 item system provides early risk assessment for high-risk diabetic feet
Experts Develop New Risk Assessment System for Diabetic Feet
This expert consultation and guideline describes the development of an early risk assessment system for high-risk diabetic feet. The consens…
A new assessment system identifies risk factors like nerve damage and circulation to help manage and prevent complications in patients with …